Augmentation of NKT and NK cell-mediated cytotoxicity by peptidoglycan monomer linked with zinc. by Mrakovcić-Sutić, Ines et al.
Augmentation of NKT and NK
cell-mediated cytotoxicity by
peptidoglycan monomer linked
with zinc
Ines MrakovÆ ci´ c- Æ Suti´ c, Biserka RadoÆ sevi´ c-StaÆ si´ cCA,
Marija  Æ Simin, Damir Muhvi´ c and Daniel Rukavina
Department of Physiology and Immunology, Faculty
of Medicine, University of Rijeka, B. Branchetta 22,
HR-51000 Rijeka, Croatia
CACorresponding Author
Tel: +385 51 651 150
Fax: +385 51 675 699
E-mail: biserr@medri.hr
BACKGROUND:  Peptidoglycan  monomer  (PGM),  which
was originally prepared by biosynthesis from culture
fluids of penicillin-treated Brevibacterium  divarica-
tum, is an immunostimulator, the activities of which
might  be improved by addition of zinc  (Zn)  to the
basic molecule.
Methods: To test the possible cytotoxic effects of this
new analogue, we analyzed the ability of PGM-Zn and
PGM to change the phenotypic profile of hepatic and
splenic mononuclear lymphatic cells and to affect the
growth of malignant T-cell line YAC-1 and syngeneic
thymocytes.
Results: Pretreatment of C57BL/6 mice primarily with
PGM-Zn  over  6  days  (10/mg/kg  intraperitoneally)
significantly enhanced the proportions of NK1.1high+,
CD4–CD8–, CD69+, and CD3intermediate/NK1.1+/IL2R-b
+
(NKT) cells in the liver, and major histocompatibility
complex class II+, CD69+, and CD8+ cells in the spleen.
Both types of cells were highly cytotoxic against YAC-
1 and syngeneic thymocytes, increasing the destruc-
tion of YAC-1 by 70% on addition of hepatic cells and
by 30%  on addition of splenic cells. Destruction of
thymocytes increased by 10 and 50%, respectively.
Conclusion: The results point to PGM-Zn as a potent
cytotoxicity-inducing  agent,  which  also  generates
autoreactive NKT cells.
Key words: NK cells, NK1.1, Intermediate T cell receptor
expressing  cells,  Cytotoxicity  to  YAC-1  and  syngeneic
thymocytes, Liver and spleen, Self-reacting NKT cells
Introduction
Bacterial  cell-wall  components,  such  as  lipopoly-
saccharide derived from Gram-negative bacteria and
peptidoglycans (PG) isolated from Gram-positive bac-
terial cell walls, are well-known immunomodulating
agents,  which  participate  in  the  immune  reaction
generated  on  antigen  or  pathogen  stimulation.1–6
Both substances in the presence of two soluble serum
proteins  (i.e.  CD14  and  lipopolysaccharide binding
protein) activate lymphoid targets through the CD14
receptor,  which  might  be  viewed  as  the  patterns
recognition  receptor  for  various  bacterial  cell-wall
components.3,4 CD14  then  recruits  peptidoglycan
monomer  (PGM)  to  members  of Toll-like  receptor
(TLR)2, which was identified as an essential compo-
nent  of  the  PG  receptor  signaling  complex  that
controls innate responses.5–7
Stimulation  of TLR proteins results  in  the release
mainly  of  pro-inflammatory  mediators  (interleukin
(IL)-1,  IL-6,  and  tumor  necrosis factor-a),  which  in
large quantities might promote infection and induce
septic  shock.7 In  lower  doses,  however,  bacterial
products  might  have  immunostimulating  and  anti-
metastatic  activities  linked  with  the  stimulation  of
both  unspecific  and  specific  immune  responses.8
Adjuvant effects have been tried to be explained by
stimulation  of  co-stimulatory  activities  in  antigen-
presenting  cells,  by  mimicking  of  co-stimulatory
signals  in  T  cells,  or  by  enhanced  uptake  of  the
antigen  by  dendritic  cells  that  already  express  co-
stimulatory molecules.8Since there is still a paucity of
data about the mechanisms leading to inflammatory
and immunomodulatory responses induced by Gram-
positive bacteria, in the present study we tested the
effects of PGM, obtained by biosynthesis from culture
fluids  of  penicillin-treated  Brevibacterium  divar-
icatum NRRL-2311,9 and its new analogue PGM-Zn
on the innate immune system.
Basically,  PGM  represents  a  water-soluble  mono-
meric structural subunit of the polymeric PG, consist-
ing  of  b1,4-linked  N-acetylmuramic  acid-N-acetyl-
D-glucosamine  disaccharide  carrying  the
pentapeptide.  Its  immunostimulating  and  antimeta-
static  activities  have  been  emphasized  in  many
experimental protocols,10–12 but the precise mecha-
nism of action of PGM is still unknown. Generally, it is
held  that  it  uses  similar  pathways  as  other  Gram-
positive bacteria.5,6This is supported also by our own
data,  showing  that  PGM  in  vitro has  a  cytokine-
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nuclear  cells,  leading  to  release  of  IL-1,  IL-6,  and
tumor  necrosis  factor-a in  the  presence  of  human
serum  or  soluble  CD14.13 Previously,  however,  we
also reported that addition of zinc might potentiate
the immunostimulatory activity of PGM.14–17The new
analogue (PGM-Zn) augmented antibody production
and isotype switching in mice sensitized with sheep
red blood cells,14 and corrected some immunosup-
pressive aspects of aging15 and cholestatic jaundice.16
We also observed that prolonged treatment of mice
with PGM-Zn may  result  in activation of  peritoneal
macrophages, which  have greater  phagocytic  activ-
ities,  as  well  as  the  ability  to  suppress  the  Con-
A-induced blastic transformation of syngeneic spleno-
cytes.17 Immunomodulatory  effects  of  PGM  and
PGM-Zn in these experiments correlated with major
histocompatibility complex (MHC) class II expression
in the liver,14 in which we also previously noticed an
accumulation of zinc during the normal humoral and
cellular immune response.18
Bearing  in  mind  the  crucial  role  of  the  hepatic
natural killer (NK) cells and NKT cells in the control
of immune survielance,19,20 and evidence about the
antitumor effects of PGM alone,10–12 in this study we
attempted to characterize the effects of  PGM-Zn in
comparison with  the  effect  of  PGM  alone  on  pro-
cesses of cell-mediated cytotoxicity. For this purpose,
we  determined  the  phenotype  and  function  of
hepatic  and  splenic  mononuclear  lymphatic  cells
(MNLC)  activated in  vivo by  PGM-Zn  or  PGM  and
analyzed  their  ability  to  block  the  growth  of  the
malignant T-cell line YAC-1 and syngeneic thymocytes.
The data showed that pretreatment of C57BL/6 mice,
particularly  with PGM-Zn, might  markedly  enhance
the  cytotoxicity  of  both  types  of  lymphoid  cells
against NK-sensitive targets, as well as against synge-
neic cells. Simultaneous phenotypic analysis of effec-
tor cells also suggested that this cytotoxicity in the
liver  might  be  linked  with  activation  of  NK1.1+,
CD3intermediate, IL-2Rb+ NKT cells, and in the spleen
with activation of cytotoxic CD8+T cells.
Materials and methods
Animals
We  used  inbred,  2-  to  3-month  old,  male  C57BL/6
mice. The  animals  were  housed in  standard plastic
cages, allowed access to standard mouse food pellets
and  water ad  libitum,  and  exposed to  the  natural
light/dark cycle.
Treatment with PGM-Zn
Immunomodulating  agents  PGM  (GlcNAc-MurNAc-
L-Ala-D-iso-Gln-meso-diamminopimelic acid (w-NH2)-
D-Ala-D-Ala)  and  PGM  linked  with  zinc  (PGM-Zn),
(Pliva,  Zagreb,  Croatia)  were  prepared  by  biosyn-
thesis  from  the  culture  fluids  of  Brevibacterium
divaricatum NRRL-2311,  as  an  apyrogenic,  water-
soluble  substance devoid of  any toxic effects.9 The
samples  used  in  this  study  contained  less  than
0.015ng of endotoxin/mg of PGM, according to the
limulus amebocyte lysate test (Pyrostat Kit; Millipore,
Bedford, Massachusetts). In  the morning  every sec-
ond day, the mice were injected with PGM-Zn or PGM
dissolved in phosphate-buffered saline (PBS) (10mg/
kg of body weight, intraperitoneally (i.p.)) for 6 days
(total  dose, 30mg/kg).  Mice  in  the  control  groups
were treated with the same volume (0.5ml) of PBS.
Two days after the last injection, the animals were
sacrificed to isolate the hepatic and splenic MLNC.
Isolation of intrahepatic lymphocytes,
splenocytes and thymocytes
Intrahepatic  lymphocytes  (IHL)  were  isolated  from
intact liver after in situ perfusion with PBS, using a
modification  of  the  method  of  Seglen,  as  we  pre-
viously  described.21 Resident  liver  MNLC were  iso-
lated by Ficoll–Hypaque density gradient centrifuga-
tion (20min at 800 ´ g). A single suspension of spleen
cells was prepared in RPMI 1640 medium (Gipco BRL,
Basel, Switzerland), after elimination of erythrocytes
by  lysing  solution. The  syngeneic  thymocytes  were
prepared in a similar way.
Cytofluorometric analysis
The surface phenotypes of resident IHL and spleno-
cytes were identified by direct immunofluorescence
analysis on FACScan (Becton Dickinson, Immunocyto-
metry  Systems,  Mountain  View,  CA,  USA),  using
CELLQuest  Software  (Quadra  650;  Macintosh).  As
primary  monoclonal antibodies (mAbs),  fluorescein
isothiocyanate-conjugatedmAbs (anti-CD8, anti-CD3,
anti-class I, anti-class II and anti-T-cell receptor (anti-
TCR) ab) and phycoerythrin-conjugatedmAbs (anti-
CD4, anti-CD25, anti-CD5, anti-CD44, anti-CD54, anti-
CD69, anti-CD30, anti-NK-1.1,  and anti-TCR  gd and
anti-IL2R-b chain) were used, purchased from Becton
Dickinson. All  samples  had  adequate  isotypic  con-
trols.  Propidium  iodide  (PI)  (Sigma,  St  Louis,  MO,
USA) (1mg/ml) stained dead cells were excluded by
electronic  gating.  Relative  fluorescence  intensities
were expressed in the log scale, with 1 ´ 104 cells.
Flow cytometry cytotoxicity assay
Functional NK cell assays were performed with PKH-
26 (orange)-labeled YAC-1 or syngeneic thymocytes as
target cells following the manufacturer’s instructions
(PKH-26  Red  Fluorescent  Cell  Linker  Kit;  Sigma
Biosciences, St Louis, MO, USA). For this purpose, IHL
and  splenocytes  were  incubated  for  2h  with  1 ´
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ratios in a final volume of 200ml at 37°C in a 5% CO2
atmosphere. After washing in fluorescence-activated
cell sorter (FACS) medium, 200ml of PI (concentration,
10mg/ml) were added and the percentage of dead cells
was measured by flow cytometry. The destroyed cells
were  counted by  detecting  cells  with  both  orange
(PKH-26) and red (PI) fluorescence.
Statistical analysis
Data were  analyzed using  the  Sigma  Plot  Scientific
Graphing System, Version 1.02. Statistical significance
was calculated by Mann–Whitney U test. The differ-
ences were considered significant when p < 0.05.
Results
Effects of PGM-Zn pretreatment on phenotypic
profile of MNLC in the liver and spleen
Six days after i.p. treatment with PGM-Zn (daily dose,
10mg/kg),  the  proportion  of  several  subtypes  of
lymphoid cells in the liver and spleen had changed
(Fig. 1). The most prominent changes in the liver were
significant increases in the proportion of CD4–CD8–
(double  negative),  NK1.1high+,  and  CD69+ cells,
which increased from 55.5 ± 1.7 to 65.6 ± 3.1% (p <
0.05), from 27.8 ± 3.4 to 37.7 ± 2.5% (p < 0.01), and
from  35.3  ±  2.6  to  46.5  ±  2.6%  (p <  0.01),
respectively. Double labeling, however, revealed that
most of PGM-Zn-induced hepatic MNLC belong to the
population  of  CD3int,  NK1.1int,  IL-2Rb+ cells  (i.e.
typical NKT cells) (Fig. 2). Their percentage after the
PGM-Zn arose more than after treatment with PGM
alone (increase from 10.3% to 27.2%, or from 10.3% to
17.2%,  respectively).  In  the  spleen,  however,  sig-
nificant  increases in  the proportion of  CD8+ (from
14.0 ± 0.3 to 16.3 ± 0.7%, p < 0.05), MHC class II+
(from 53.0 ± 2.6 to 60.3 ± 1.1%, p < 0.01), and CD69+
(from  1.5  ± 0.2  to 3  ± 0.3%,  p <  0.05)  cells were
observed, together with a decrease in the proportion
of CD3+ cells (from 37.1 ± 0.9 to 34 ± 0.6%, p < 0.01)
(Fig.  1). Double  labeling  also showed that PGM-Zn-
induced changes of NKT cells were in the spleen less
expressed than in the liver (Fig. 3). PGM alone in both
organs induced similar changes, but they were always
significantly lower that these obtained by PGM-Zn.
Cytotoxicity of hepatic and splenic MNLC
activated by PGM-Zn and PGM against YAC-1
To  test  the  ability  of  PGM-Zn  and  PGM-activated
intrahepatic and splenic MNC to act against the NK-
sensitive  malignant T-cell  line YAC-1,  labeled  target
cells were exposed to killer cells in different killer-to-
target  ratios  (Fig.  4). The  data,  analyzed  after  2h,
showed that PGM-Zn increased, in a dose-dependent
manner, the cytotoxicity of both effectors, increasing
the  destruction  of YAC-1  by  70%  after  addition  of
hepatic MLNC cells (from 5 to 76% at an effector:tar-
get ratio of 50:1, p < 0.01) and by 30% from baseline
after the addition of splenic cells (from 10 to 40%, p
<  0.05).  Although  PGM-activated  intrahepatic  and
splenic cells were more cytotoxic than control MNLC
(p <  0.01),  this  cytotoxicity  at  all  ratios  was  sig-
nificantly lower than cytotoxicity of PGM-Zn-activated
cells  (p <  0.01). A  similar  but  less  expressed  stim-
ulatory  effect  was  obtained  with  PGM-Zn-activated
peripheral  blood  mononuclear  cells,  which  in  the
control group showed very small  cytotoxic activity
against YAC-1 (data not shown).
Cytotoxicity of hepatic and splenic MNLC
activated by PGM-Zn and PGM against
syngeneic thymocytes
To test the possibility that during the treatment of mice
with PGM-Zn or PGM autoreactive clones of NKT cells
were  generated,  hepatic  and  splenic  MNLC  were
incubated  also  with  labeled  syngeneic  thymocytes
(Fig. 5). The data showed that PGM-Zn augmented the
cytotoxicity of hepatic MNLC by 10% (from 10 to 20%,
at  an  effector:target  ratio  of  50:1).  Splenic  MNLC,
obtained from PGM-Zn-treated mice, however, were
more cytotoxic for syngeneic thymocytes than control
MNLC, even at a very low effector:target ratio (50% at
the ratio 6.25:1, p < 0.01).
Cytotoxicity by PGM-Zn activated lymphoid cells
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FIG.  1.  Phenotypic  profiles  of  hepatic  and  splenic  MNLC
obtained from  C57BL/6  mice  pretreated over  6  days  with
three doses of PGM-Zn, PGM (10mg/kg i.p.) or with saline
solution (n = 7). Mean ± standard errors are presented. *p <
0.05, **p < 0.01.I. Mrakovcic- ÆSuti´ c et al.
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FIG. 2. FACS profiles of two-color immunofluorescence staining of hepatic MNLC after in vivo treatment with PGM-Zn, PGM
or medium, shown as a representative result of three isolated experiments.
FIG. 3. FACS profiles of two-color immunofluorescence staining of splenic MNLC after in vivo treatment with PGM-Zn, PGM or
medium, shown as a representative result of three isolated experiments.Discussion
The data clearly show that PGM and especially PGM-
Zn,  given  in vivo,  enhance the  antitumor cytotox-
icity  and  autoreactivity  of  hepatic  and  splenic
MNLC.  In  the  liver,  the  effect  seems  to  be  linked
with  the  increased  proportion  of  activated  CD3int
NK1.1+ cells, which after the treatment with PGM-
Zn  were  present  in  an  almost  threefold  greater
proportion than in the control groups of mice (arose
from  10.28%  to  27.19%). Almost  all  of  them  were
also  IL-2Rb+ cells,  although  PGM-Zn  increased also
the  proportion  of  the  NK1.1high+ and  CD3– cell
populations (i.e. NK cells).
The described phenotype is characteristic for the
population  of  intermediate,  NKT  cells  whose  link
with the liver is particularly emphasized.19,20Support-
ive elements of their differentiation is IL-7, which is
produced by hepatocytes, and IL-12, IL-15 and IL-18,
which  are  produced  by  Kupffer  or  endothelial
cells.22–24 Although NKT cells phenotypically repre-
sent  marked  heterogeneity,  they  usually  co-express
markers that  belong  to T  and  NK lineage,  and  are
characterized by a highly  restricted TCR repertoire,
made of an invariant TCRa chain, Va14-Ja281, asso-
ciated  with  polyclonal  Vb8,  Vb7,  and Vb2 TCR  b
chains.22–27 It was hypothesized that they represent
primordial  T  cells,  which  stay  at  an  intermediate
phylogenetic position between NK-derived and thy-
mus-derived T cells.22,23The current dogma is that this
novel lineage of lymphocytes are selected by the non-
classical MHC class I-like molecule, CD1d, which in
mice is expressed on dendritic cells, B cells, T cells,
macrophages and  hepatocytes.27,28 Unlike  the  con-
ventional MHC molecules, which bind short peptides
in  their  antigen-binding  groove  for  presentation  to
either CD4+or CD8+T cells bearing abTCRs, the CD1
molecules are involved in  the presentation of  lipid
and glycolipid antigens.25–30The hydrophobic part of
these antigens most probably binds in the CD1 ligand-
binding groove, whereas the polar headgroup of these
antigens appears to make direct contact with the TCR
and  determines specific  recognition.29,30 In  such  a
way, CD1 molecules also display diverse, covalently
attached carbohydrates to T cells,  that then help  B
cells to mount an antibody response to polysacchar-
ide antigens.31 CD1-restricted NKT and T cells there-
fore play  an important role in  host defense against
microbial infection, but participate also in the recog-
nition  of  distinct  self-antigens,28–32 since  natural
Cytotoxicity by PGM-Zn activated lymphoid cells
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FIG. 4. Destruction of labeled YAC-1 target cells by hepatic
(A) and splenic (B) MNLC obtained from mice pretreated with
PGM-Zn or saline solution. Results are presented as mean ±
standard error (n = 7). *p < 0.05, **p < 0.01, ***p < 0.001.
FIG.  5.  Destruction  of  labeled  syngeneic  target  cells  by
hepatic  (A)  and  splenic  (B)  MNLC  obtained  from  mice
pretreated  with  PGM-Zn  or  saline  solution.  Results  are
presented as mean ± standard error (n = 7). *p < 0.05, **p <
0.01, ***p < 0.001.ligands for CD1 molecules might be the glycosylphos-
phatidylinositol anchors and phosphoinositol manno-
sides,33 various metabolites produced by the cells,34
as well as stress proteins MICA and MICB,35 support-
ing  the  hypothesis  that  NKT cells  represent  autor-
eactive,  forbidden,  clones  of  T  cells,  which  after
activation might eliminate abnormal self-cells.22–26
Our data showing increased cytotoxicity of hepatic
MNLC after in vivo treatment of mice with PGM-Zn
against NK-sensitive and syngeneic targets are, there-
fore, in agreement with current knowledge of induc-
tion and function  of  hepatic NKT cells in bacterial
infection.22,28,36 We are, however, among the first to
show that addition of  Zn  to PGM might  potentiate
these activities. Owing to the relevance of  zinc for
good functioning of the entire immune system, where
Zn is acting as a catalyst, structural (zinc fingers) and
regulatory  ion,37–41 the  observed  effects  obviously
might  be  obtained  by  different  mechanisms.
Enhanced cytotoxicity probably includes the effect of
Zn2+ on the level of ‘NK cell immune synapse’, where
Zn  modulates specifically  the  negative  signal  trans-
mitted  to  the  NK  cells,  after  binding  of  killer  cell
immunoglobulin-like  receptors to  MHC  class  I  pro-
teins.42,44 However,  owing  to  the  possibility  that
PGM-Zn acts as superantigen, which markedly enhan-
ces the activities of T and B lymphocytes, it could be
hypothesized that some changes occurred also at the
level of MHC class II molecules, outside the peptide-
binding  groove,  since  co-ordination  of  Zn2+ is
required  for  high  binding  of  superantigen  to  this
place.44Besides numerous other possibilities,37–41we
would like also to emphasize the crucial role of zinc
for  the  regulation  of  apoptosis  and  cell  prolifera-
tion,45,46 because  this  evidence  permits  one  to
speculate that PGM-Zn was directly involved in the
apoptotic  process  and  CD1  presentation  of  self-
antigens.  Namely,  during  the  infection,  activated
monocytes  and  other  cells  undergo  spontaneous
apoptosis,  which  involves  Fas/Fas  ligand  interac-
tions.47–49 Moreover, since binding of bacterial toxins
and  bacterial lipoproteins  through TLR2  signals  for
apoptosis through the myeloid differentiation factor
88  via  a  pathway  involving  Fas-associated  death
domain protein and caspase 8, as well as for cytokine
production,50 there is a possibility that some of the
PGM-Zn-induced modifications of cell-mediated cyto-
toxicity occurred on the level of Toll-like receptor-2,
which  is  a  ligand  also  for  peptidoglycans,  released
from Gram-positive bacteria.1–6 Furthermore, since it
is known that the intracellular content released from
dying  cells  may  stimulate  the  generation  of  autor-
eactive NKT,24,27,32,33–35 as well as adaptive immune
responses,51 it  could be speculated that, in  such  a
way, PGM-Zn has augmented also the cytotoxicity of
splenic MNLC to NK-sensitive and syngeneic targets
(Fig. 5). The recent finding of a high-speed commu-
nication network between the NKT cells, generated
in  vivo after  treatment with Alpha-GalCer,  and  the
adaptive  immune  systems52 seems  to  support  this
conclusion.
Taken  together,  although  the  further  character-
istics of the effects of  PGM-Zn on innate immunity
remain to  be  elucidated, our data provide  the first
evidence  that  addition  of  zinc  to  PGM  markedly
enhances the  generation  of  hepatic  NKT  cells  and
increases  the  cytotoxic  potential  of  hepatic  and
splenic  MNLC  against  NK-sensitive  and  syngeneic
targets.
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